Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Research Report 2021
Table of Contents1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Overview
1.1 Product Overview and Scope of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
1.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Segment by Type
1.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Serotype 6B
1.2.3 7F Serotype
1.2.4 Serotype 9V
1.2.5 14 Serotype
1.2.6 Serotype 18C
1.2.7 Serotype 19A
1.2.8 19F Serotype
1.2.9 23F Serotype
1.2.10 24F Serotype
1.2.11 Other
1.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Segment by Application
1.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Comparison by Application: (2021-2027)
1.3.2 Infants from 6 Weeks to 15 Months Old
1.3.3 Children Aged 15 Months to 5 Years
1.4 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size Estimates and Forecasts
1.4.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue 2016-2027
1.4.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2016-2027
1.4.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Region: 2016 Versus 2021 Versus 2027
2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Competition by Manufacturers
2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Manufacturers (2016-2021)
2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Manufacturers (2016-2021)
2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Average Price by Manufacturers (2016-2021)
2.4 Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Sites, Area Served, Product Type
2.5 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Competitive Situation and Trends
2.5.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Players Market Share by Revenue
2.5.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Retrospective Market Scenario by Region
3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Facts & Figures by Country
3.3.1 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country
3.3.2 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Facts & Figures by Country
3.4.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country
3.4.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Facts & Figures by Region
3.5.1 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region
3.5.2 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Facts & Figures by Country
3.6.1 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country
3.6.2 Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Facts & Figures by Country
3.7.1 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country
3.7.2 Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Historic Market Analysis by Type
4.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2016-2021)
4.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Type (2016-2021)
4.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type (2016-2021)
5 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Historic Market Analysis by Application
5.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2016-2021)
5.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Application (2016-2021)
5.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Minhai Bio
6.2.1 Minhai Bio Corporation Information
6.2.2 Minhai Bio Description and Business Overview
6.2.3 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolio
6.2.5 Minhai Bio Recent Developments/Updates
6.3 Kexing Bio
6.3.1 Kexing Bio Corporation Information
6.3.2 Kexing Bio Description and Business Overview
6.3.3 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolio
6.3.5 Kexing Bio Recent Developments/Updates
6.4 Cansino Bio
6.4.1 Cansino Bio Corporation Information
6.4.2 Cansino Bio Description and Business Overview
6.4.3 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolio
6.4.5 Cansino Bio Recent Developments/Updates
6.5 Lanzhou Biological Preparations Institute
6.5.1 Lanzhou Biological Preparations Institute Corporation Information
6.5.2 Lanzhou Biological Preparations Institute Description and Business Overview
6.5.3 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Portfolio
6.5.5 Lanzhou Biological Preparations Institute Recent Developments/Updates
7 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Cost Analysis
7.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
7.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors List
8.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Customers
9 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Dynamics
9.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industry Trends
9.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Growth Drivers
9.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Challenges
9.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Restraints
10 Global Market Forecast
10.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Type (2022-2027)
10.1.2 Global Forecasted Revenue of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Type (2022-2027)
10.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Application (2022-2027)
10.2.2 Global Forecasted Revenue of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Application (2022-2027)
10.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Region (2022-2027)
10.3.2 Global Forecasted Revenue of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesTable 1. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Covered in This Study
Table 5. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Manufacturers (2016-2021)
Table 7. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Sites and Area Served
Table 11. Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2016-2021) & (K Units)
Table 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2016-2021)
Table 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2016-2021) & (K Units)
Table 19. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2016-2021)
Table 20. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2016-2021)
Table 22. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2016-2021) & (K Units)
Table 23. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2016-2021)
Table 24. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2016-2021)
Table 30. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2016-2021) & (K Units)
Table 31. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2016-2021)
Table 32. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Country (2016-2021)
Table 38. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units) by Type (2016-2021)
Table 39. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Type (2016-2021)
Table 40. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (Million US$) by Type (2016-2021)
Table 41. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Type (2016-2021)
Table 42. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price (US$/Unit) by Type (2016-2021)
Table 43. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units) by Application (2016-2021)
Table 44. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Application (2016-2021)
Table 45. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue (Million US$) by Application (2016-2021)
Table 46. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Application (2016-2021)
Table 47. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price (US$/Unit) by Application (2016-2021)
Table 48. Pfizer Corporation Information
Table 49. Pfizer Description and Business Overview
Table 50. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product
Table 52. Pfizer Recent Developments/Updates
Table 53. Minhai Bio Corporation Information
Table 54. Minhai Bio Description and Business Overview
Table 55. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product
Table 57. Minhai Bio Recent Developments/Updates
Table 58. Kexing Bio Corporation Information
Table 59. Kexing Bio Description and Business Overview
Table 60. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product
Table 62. Kexing Bio Recent Developments/Updates
Table 63. Cansino Bio Corporation Information
Table 64. Cansino Bio Description and Business Overview
Table 65. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product
Table 67. Cansino Bio Recent Developments/Updates
Table 68. Lanzhou Biological Preparations Institute Corporation Information
Table 69. Lanzhou Biological Preparations Institute Description and Business Overview
Table 70. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product
Table 72. Lanzhou Biological Preparations Institute Recent Developments/Updates
Table 73. Production Base and Market Concentration Rate of Raw Material
Table 74. Key Suppliers of Raw Materials
Table 75. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors List
Table 76. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Customers List
Table 77. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Trends
Table 78. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Growth Drivers
Table 79. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Challenges
Table 80. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Restraints
Table 81. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Type (2022-2027) & (K Units)
Table 82. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share Forecast by Type (2022-2027)
Table 83. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 84. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share Forecast by Type (2022-2027)
Table 85. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Application (2022-2027) & (K Units)
Table 86. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share Forecast by Application (2022-2027)
Table 87. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 88. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share Forecast by Application (2022-2027)
Table 89. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Forecast by Region (2022-2027) & (K Units)
Table 90. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share Forecast by Region (2022-2027)
Table 91. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 92. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share Forecast by Region (2022-2027)
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of FiguresFigure 1. Product Picture of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Figure 2. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Type in 2020 & 2027
Figure 3. Serotype 6B Product Picture
Figure 4. 7F Serotype Product Picture
Figure 5. Serotype 9V Product Picture
Figure 6. 14 Serotype Product Picture
Figure 7. Serotype 18C Product Picture
Figure 8. Serotype 19A Product Picture
Figure 9. 19F Serotype Product Picture
Figure 10. 23F Serotype Product Picture
Figure 11. 24F Serotype Product Picture
Figure 12. Other Product Picture
Figure 13. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Application in 2020 & 2027
Figure 14. Infants from 6 Weeks to 15 Months Old
Figure 15. Children Aged 15 Months to 5 Years
Figure 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size 2016-2027 (US$ Million)
Figure 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales 2016-2027 (K Units)
Figure 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 20. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Share by Manufacturers in 2020
Figure 21. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Share by Manufacturers in 2020
Figure 22. The Global 5 and 10 Largest 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Players: Market Share by Revenue in 2020
Figure 23. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region (2016-2021)
Figure 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share by Region in 2020
Figure 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region (2016-2021)
Figure 27. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Region in 2020
Figure 28. United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Canada 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Germany 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. France 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. U.K. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Italy 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Russia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Australia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Taiwan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Indonesia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Thailand 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Malaysia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Mexico 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Brazil 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Argentina 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Colombia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Turkey 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. Saudi Arabia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 50. UAE 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 51. Sales Market Share of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Type (2016-2021)
Figure 52. Sales Market Share of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Application (2016-2021)
Figure 53. Sales Market Share of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Application in 2020
Figure 54. Revenue Share of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Application (2016-2021)
Figure 55. Revenue Share of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by Application in 2020
Figure 56. Manufacturing Cost Structure of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Figure 57. Manufacturing Process Analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
Figure 58. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industrial Chain Analysis
Figure 59. Channels of Distribution
Figure 60. Distributors Profiles
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed